CD5 CART
Phase 1Cell therapy
CD5 CART is one of 82 biologic programs targeting T-cell acute lymphoblastic leukemia. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
408 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Oncovin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Iclusig
TakedaPhase 3
Medrol
PfizerPhase 3
Cellcept
RochePhase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Eptanemab
UCBPhase 3
Prograf
VVeloxis Pharmaceuticals
Phase 3
Zinecard
PfizerPhase 3
Busulfex
Akero TherapeuticsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
T-cell acute lymphoblastic leukemia1 trial
Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Terminated·—·Phase 1·NCT05032599·19 enrolled
Acute Lymphoblastic Leukemia1 trial
Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma
Withdrawn·—·Phase 1·NCT05487495
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD5 CART. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Phase 1[1]
- Company
- BBeijing Boren Hospital